Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea.
Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea; Institute for Innovation in Digital Healthcare, Yonsei University Health System, Seoul, Republic of Korea.
Thromb Res. 2024 Mar;235:32-40. doi: 10.1016/j.thromres.2024.01.016. Epub 2024 Jan 25.
Thromboembolic events exhibit increased prevalence in patients with cancer and can negatively affect prognoses. We investigated whether statin treatment would reduce thromboembolic risk in patients with cancer.
We conducted a nested case-control study using a Korean nationwide health claims database. The study included patients newly diagnosed with cancer without a prior history of cardiovascular disease between 2014 and 2016. Cases who developed arterial thromboembolism (ATE) or venous thromboembolism (VTE) after cancer diagnosis and three individually matched controls were selected. Conditional logistic regression was used to assess the association between thromboembolic risk and statin therapy after cancer diagnosis.
Among 455,805 newly diagnosed patients with cancer followed for a mean of 4.3 ± 2.0 years, 22,249 patients developed thromboembolic events (ATE: 6341, VTE: 15,908), resulting in an incidence rate of 1133 per 100,000 person-years. The nested case-control study included 21,289 cases with thromboembolic events and 63,867 controls. Statin use was less frequent in the case group (18.0 % vs. 23.7 %). Statin treatment was associated with a lower risk of thromboembolic events (adjusted odds ratio [OR] 0.70; 95 % confidence interval [CI] 0.67-0.73). This association was observed for both ATE (adjusted OR 0.68; 95 % CI 0.63-0.74) and VTE (adjusted OR 0.71; 95 % CI 0.67-0.75). Longer statin use and better adherence were also associated with lower risk for thromboembolic events. Statin treatment was significantly associated with fewer thromboembolic events in most cancer types.
Statin use was associated with lower risk for thromboembolic events in patients newly diagnosed with cancer.
癌症患者血栓栓塞事件的发生率增加，并可能对预后产生负面影响。我们研究了他汀类药物治疗是否会降低癌症患者的血栓栓塞风险。
我们使用韩国全国健康索赔数据库进行了一项嵌套病例对照研究。该研究纳入了 2014 年至 2016 年间新诊断为癌症且无心血管疾病既往史的患者。选择癌症诊断后发生动脉血栓栓塞（ATE）或静脉血栓栓塞（VTE）的病例和 3 名单独匹配的对照。采用条件逻辑回归评估癌症诊断后血栓栓塞风险与他汀类药物治疗之间的关系。
在 455805 例平均随访时间为 4.3±2.0 年的新诊断癌症患者中，有 22249 例发生血栓栓塞事件（ATE：6341 例，VTE：15908 例），发生率为 1133/100000 人年。嵌套病例对照研究纳入了 21289 例血栓栓塞事件病例和 63867 例对照。病例组他汀类药物使用率较低（18.0% vs. 23.7%）。他汀类药物治疗与血栓栓塞事件风险降低相关（调整后的优势比[OR]0.70；95%置信区间[CI]0.67-0.73）。ATE（调整后的 OR 0.68；95%CI 0.63-0.74）和 VTE（调整后的 OR 0.71；95%CI 0.67-0.75）均观察到这种相关性。他汀类药物使用时间较长和依从性较好也与血栓栓塞事件风险降低相关。他汀类药物治疗与大多数癌症类型的血栓栓塞事件发生率降低显著相关。
他汀类药物治疗与新诊断癌症患者的血栓栓塞事件风险降低相关。
Zotero 插件